FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his 'Liberation Day' ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK PLC closed 21.39% short of its 52-week high of £18.24, which the company reached on May 16th.

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

Sanofi hires former GSK development head Chris Corsico as global R&D head, replacing Dietmar Berger who left for Gilead. Move aligns with €2B R&D investment strategy.

GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...